MedPath

Evaluation of acute and long-term outcomes of lysis therapy of arterial occlusions with tissue-specific plasminogen activator (rt-PA).

Conditions
I70.20
Registration Number
DRKS00030930
Lead Sponsor
niversitäts-Herzzentrum Freiburg-Bad Krozingen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
1238
Inclusion Criteria

All patients treated with lysis therapy for peripheral arterial disease of the lower extremities

Exclusion Criteria

- Patients in whom lysis therapy has not been used.
- Patients in whom lysis therapy has been used for recanalization of deep vein thrombosis or upper extremity vascular occlusion.

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-Peri-interventional complication rate defined as complications that affected therapy or required surgical or other correction, or prolonged hospital stay. Complications are divided into Serious Adverse Event (SAE) and (Adverse Event) AE. <br>- Acute Intervention Success, i.e., establishment of blood flow in the lysed vessel area defined as complete clearance of the occlusion or sufficient clearance to reveal an underlying etio- logical factor that was responsible for the occlusion.
Secondary Outcome Measures
NameTimeMethod
- Predictors of complication<br>- Leg preservation acutely and after 6, 12 and 24 months<br>- Re-intervention rate at the target lesion (target lesion revascularization, TLR) and at the target vessel (target vessel revascularization, TVR)<br>- Change in clinical symptoms using the Rutherford-Becker classification at 6, 12, and 24 months<br>- Change of the Ankle-Brachial-Index after 6, 12 and 24 months
© Copyright 2025. All Rights Reserved by MedPath